JP2016504389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504389A5 JP2016504389A5 JP2015551862A JP2015551862A JP2016504389A5 JP 2016504389 A5 JP2016504389 A5 JP 2016504389A5 JP 2015551862 A JP2015551862 A JP 2015551862A JP 2015551862 A JP2015551862 A JP 2015551862A JP 2016504389 A5 JP2016504389 A5 JP 2016504389A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- mgbg
- fingolimod
- disease
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims 17
- KKGQTZUTZRNORY-UHFFFAOYSA-N Fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 229960000556 fingolimod Drugs 0.000 claims 11
- 208000004275 Demyelinating Disease Diseases 0.000 claims 8
- 229960003539 Mitoguazone Drugs 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- LDCRTTXIJACKKU-ONEGZZNKSA-N Dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 4
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 4
- 108010005716 Interferon beta-1a Proteins 0.000 claims 4
- 229960004461 Interferon beta-1a Drugs 0.000 claims 4
- 108010005714 Interferon beta-1b Proteins 0.000 claims 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 4
- 229960001156 Mitoxantrone Drugs 0.000 claims 4
- 108010035649 Natalizumab Proteins 0.000 claims 4
- UTNUDOFZCWSZMS-YFHOEESVSA-N Teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims 4
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 4
- 229960004419 dimethyl fumarate Drugs 0.000 claims 4
- 229960003776 glatiramer acetate Drugs 0.000 claims 4
- 229960003161 interferon beta-1b Drugs 0.000 claims 4
- 229960005027 natalizumab Drugs 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229960000331 teriflunomide Drugs 0.000 claims 4
- GKWPCEFFIHSJOE-UHFFFAOYSA-N Laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 229960004577 laquinimod Drugs 0.000 claims 3
- 206010068202 Leukodystrophy Diseases 0.000 claims 2
- 208000008795 Neuromyelitis Optica Diseases 0.000 claims 2
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 2
- 206010036807 Progressive multifocal leukoencephalopathy Diseases 0.000 claims 2
- 210000000278 Spinal Cord Anatomy 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000002757 inflammatory Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102100004948 ABCD1 Human genes 0.000 claims 1
- 102100001910 ASPA Human genes 0.000 claims 1
- 101700019344 ASPA Proteins 0.000 claims 1
- 201000000013 Alexander disease Diseases 0.000 claims 1
- 206010067608 Canavan disease Diseases 0.000 claims 1
- 206010010252 Concentric sclerosis Diseases 0.000 claims 1
- 206010061811 Demyelinating polyneuropathy Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 1
- 201000011451 Krabbe disease Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010024381 Leukodystrophy Diseases 0.000 claims 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 102100004920 PEX7 Human genes 0.000 claims 1
- 108060006186 PHYH Proteins 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 206010034695 Pernicious anaemia Diseases 0.000 claims 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 208000009174 Transverse Myelitis Diseases 0.000 claims 1
- 230000001919 adrenal Effects 0.000 claims 1
- 201000011452 adrenoleukodystrophy Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 201000011442 metachromatic leukodystrophy Diseases 0.000 claims 1
- 230000023105 myelination Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
Claims (22)
- 脱髄疾患を有する対象における脱髄の治療または予防のための医薬の製造における、メチルグリオキサールビス（グアニルヒドラゾン）（“ＭＧＢＧ”）の使用。
- 脱髄疾患の治療または予防のための医薬の製造における、メチルグリオキサールビス（グアニルヒドラゾン）（“ＭＧＢＧ”）、ならびにインターフェロンβ−１ａ、インターフェロンβ−１ｂ、グラチラマー酢酸塩、ミトキサントロン、ナタリズマブ、フィンゴリモド、フマル酸ジメチル、およびテリフルノミドから選択される薬剤、の使用。
- 他方の薬剤がフィンゴリモドである、請求項２に記載の方法。
- ＭＧＢＧ、ならびにインターフェロンβ−１ａ、インターフェロンβ−１ｂ、グラチラマー酢酸塩、ミトキサントロン、ナタリズマブ、フィンゴリモド、ラキニモド、フマル酸ジメチル、およびテリフルノミドから選択される別の薬剤を、薬学的に許容される担体と一緒に含む、薬学的組成物。
- 他方の薬剤がフィンゴリモドである、請求項４に記載の薬学的組成物。
- 脱髄疾患の進行の予防のための医薬の製造における、メチルグリオキサールビス（グアニルヒドラゾン）（“ＭＧＢＧ”）の使用。
- インターフェロンβ−１ａ、インターフェロンβ−１ｂ、グラチラマー酢酸塩、ミトキサントロン、ナタリズマブ、フィンゴリモド、ラキニモド、フマル酸ジメチル、およびテリフルノミドから選択される薬剤の投与をさらに含む、請求項６に記載の使用。
- 前記薬剤がフィンゴリモドである、請求項７に記載の使用。
- 患者における進行型多発性硬化症の治療のための医薬の製造における、メチルグリオキサールビス（グアニルヒドラゾン）（“ＭＧＢＧ”）の使用。
- 脱髄疾患を有する患者における自己免疫応答の始動期の予防またはその重症度の低減のための医薬の製造における、メチルグリオキサールビス（グアニルヒドラゾン）（“ＭＧＢＧ”）の使用。
- 脱髄疾患を有する患者における自己免疫応答の始動期および増幅期の予防またはその重症度の低減のための医薬の製造における、メチルグリオキサールビス（グアニルヒドラゾン）（“ＭＧＢＧ”）の使用。
- 前記脱髄疾患が、多発性硬化症、視神経炎、特発性炎症性脱髄疾患、ギラン−バレー症候群、慢性炎症性脱髄性多発ニューロパチー、横断性脊髄炎、バロー同心円性硬化症、悪性貧血、橋中心髄鞘崩壊症、脊髄癆、視神経脊髄炎（ＮＭＯ）、進行性多巣性白質脳症（ＰＭＬ）、抗ＭＡＧ（ミエリン関連糖タンパク質）ニューロパチー、遺伝性運動感覚性ニューロパチー（シャルコー−マリー−トゥース病）、脳腱黄色腫症（ｃｅｒｅｂｒｏｔｅｎｄｉｎｉｏｕｓ ｘａｎｔｈａｎｏｍａｔｏｓｉｓ）、ならびに、副腎白質ジストロフィー、副腎脊髄ニューロパチー、異染性白質ジストロフィー、グロボイド細胞白質ジストロフィー（クラッベ病）、カナバン病、白質消失病、アレキサンダー病、レフサム病、およびペリツェウス−メルツバッヘル病を含む白質ジストロフィーから選択される、請求項１、２、６、１０または１１に記載の使用。
- 前記脱髄疾患が多発性硬化症である、請求項１２に記載の使用。
- インターフェロンβ−１ａ、インターフェロンβ−１ｂ、グラチラマー酢酸塩、ミトキサントロン、ナタリズマブ、フィンゴリモド、ラキニモド、フマル酸ジメチル、およびテリフルノミドから選択される薬剤の投与をさらに含む、請求項１３に記載の使用。
- 前記薬剤がフィンゴリモドである、請求項１４に記載の使用。
- フィンゴリモドが１日当たり０．５ｍｇで投薬される、請求項１５に記載の使用。
- フィンゴリモドが１日当たり０．５ｍｇ未満で投薬される、請求項１５に記載の使用。
- フィンゴリモドが１日当たり０．２５ｍｇで投薬される、請求項１５に記載の使用。
- ＭＧＢＧの前記投与が経口である、請求項１４に記載の使用。
- ＭＧＢＧが２０ｍｇ／日〜４００ｍｇ／日で投薬される、請求項１９に記載の使用。
- ＭＧＢＧの前記投与が経口である、請求項９に記載の使用。
- ＭＧＢＧが２０ｍｇ／日〜４００ｍｇ／日で投薬される、請求項２１に記載の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750336P | 2013-01-08 | 2013-01-08 | |
| US61/750,336 | 2013-01-08 | ||
| US201361823276P | 2013-05-14 | 2013-05-14 | |
| US61/823,276 | 2013-05-14 | ||
| PCT/US2014/010714 WO2014110154A1 (en) | 2013-01-08 | 2014-01-08 | Methods and comp0stions for treatment of demyelinating diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018130715A Division JP2018172427A (ja) | 2013-01-08 | 2018-07-10 | 脱髄疾患の治療のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504389A JP2016504389A (ja) | 2016-02-12 |
| JP2016504389A5 true JP2016504389A5 (ja) | 2017-02-16 |
| JP6370804B2 JP6370804B2 (ja) | 2018-08-08 |
Family
ID=51167347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551862A Expired - Fee Related JP6370804B2 (ja) | 2013-01-08 | 2014-01-08 | 脱髄疾患の治療のための方法および組成物 |
| JP2018130715A Pending JP2018172427A (ja) | 2013-01-08 | 2018-07-10 | 脱髄疾患の治療のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018130715A Pending JP2018172427A (ja) | 2013-01-08 | 2018-07-10 | 脱髄疾患の治療のための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10085955B2 (ja) |
| EP (2) | EP3831372A1 (ja) |
| JP (2) | JP6370804B2 (ja) |
| CN (2) | CN105163730B (ja) |
| AU (2) | AU2014205529B2 (ja) |
| BR (1) | BR112015016189A8 (ja) |
| CA (1) | CA2896977C (ja) |
| DK (1) | DK2943189T3 (ja) |
| ES (1) | ES2859553T3 (ja) |
| HK (1) | HK1217451A1 (ja) |
| IL (1) | IL239851B (ja) |
| WO (1) | WO2014110154A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008112659A2 (en) | 2007-03-09 | 2008-09-18 | Pathologica Llc | Regulation of osteopontin |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| NZ715686A (en) | 2009-07-16 | 2017-08-25 | Pathologica Llc | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| PL2665471T3 (pl) | 2011-01-19 | 2018-06-29 | Pathologica, Llc. | Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg |
| US10085955B2 (en) | 2013-01-08 | 2018-10-02 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| EP3118621A1 (en) * | 2015-07-14 | 2017-01-18 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
| WO2017042274A1 (en) * | 2015-09-08 | 2017-03-16 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Quinoline derivates for use in treating leukodystrophy and treatment method |
| AU2017230387B9 (en) * | 2016-03-07 | 2022-08-04 | National Institute For Materials Science | Sustained drug release sheet for treating nerve damage |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| MX2019010174A (es) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. |
| JP2021521189A (ja) * | 2018-04-13 | 2021-08-26 | モデハイ シェヴィオンCHEVION, Mordechai | 脱髄の治療のための組成物及び方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4201788A (en) | 1976-10-20 | 1980-05-06 | University Patents, Inc. | Process for alleviating proliferative skin diseases |
| US5614557A (en) | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
| US4520031A (en) | 1981-06-01 | 1985-05-28 | The United States Of America As Represented By The Secretary Of Department Of Health And Human Services | Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone |
| US5580715A (en) | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| US5698563A (en) | 1995-01-13 | 1997-12-16 | Alteon Inc. | Bis- hydrazones! |
| EP1459747A3 (en) | 1996-09-13 | 2004-12-15 | University Of Florida Research Foundation, Inc. | Method of inhibiting biosynthesis of Elf5A |
| AR009380A1 (es) | 1996-10-21 | 2000-04-12 | Sumitomo Chemical Co | Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico |
| US6083496A (en) | 1996-10-22 | 2000-07-04 | Universite Laval | Polyamine transport inhibitors |
| WO1999003823A2 (en) | 1997-07-15 | 1999-01-28 | Oridigm Corporation | Novel polyamine analogues as therapeutic and diagnostic agents |
| US5889061A (en) | 1997-10-15 | 1999-03-30 | Wisconsin Alumni Research Foundation | Conformationally restricted polyamines |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| US8198334B2 (en) | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| US6169115B1 (en) | 1998-05-22 | 2001-01-02 | Rima Kaddurah-Daouk | Use of aminoguanidine analogs for the treatment of diseases of the nervous system |
| JP4743673B2 (ja) | 1999-04-30 | 2011-08-10 | プロゲン ファーマシューティカルズ， インコーポレイテッド | ポリアミンおよび治療におけるそれらの使用 |
| US6544541B1 (en) | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
| MXPA02008023A (es) * | 2000-02-18 | 2005-06-30 | Yeda Res & Dev | Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar. |
| JP2004513136A (ja) | 2000-11-08 | 2004-04-30 | スリル バイオメディカル コーポレーション | 抗癌剤として有用な新規ポリアミンアナログ−アミノ酸結合体 |
| US7754765B2 (en) | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
| JP4253503B2 (ja) | 2001-01-08 | 2009-04-15 | メディクエスト セラピューティックス インク | 疎水性ポリアミン類似体及びそれらの使用方法 |
| EP1413315A4 (en) | 2001-08-03 | 2006-08-16 | Takeda Pharmaceutical | DRUGS WITH CONTINUOUS RELEASE |
| WO2003013245A1 (en) | 2001-08-07 | 2003-02-20 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
| EP1425380A4 (en) | 2001-08-15 | 2004-12-22 | Univ California | RETROVIRUS ISOLATED FROM SHEATH HISTIOCYTES IN THE SHEATH CELL SYMPHOM |
| JP2005510524A (ja) * | 2001-11-16 | 2005-04-21 | アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド | ポリアミン経路の調節による神経変性障害の治療 |
| AU2002357748A1 (en) * | 2001-11-21 | 2003-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
| US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| EP1389480A1 (en) * | 2002-08-14 | 2004-02-18 | Mondobiotech Interferon SA | Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
| WO2004069174A2 (en) | 2003-01-31 | 2004-08-19 | Slil Biomedical Corporation | Monitoring and treatment of amyotrophic lateral sclerosis |
| ES2320767T3 (es) * | 2003-04-08 | 2009-05-28 | Novartis Ag | Composiciones farmaceuticas solidas que comprenden un agonista del receptor s1p y un alcohol de azuzar. |
| RU2375048C2 (ru) | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
| US20050025825A1 (en) | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
| WO2005041988A1 (en) | 2003-10-22 | 2005-05-12 | University Of Florida | Method and composition for pain amelioration |
| AU2004319105A1 (en) | 2004-03-29 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
| WO2005107801A2 (en) | 2004-04-29 | 2005-11-17 | The Regents Of The University Of Colorado | Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies |
| EP1871367A2 (en) | 2005-01-28 | 2008-01-02 | Xanthus Pharmaceuticals, Inc. | Compounds for treating inflammatory and demyelinating diseases |
| EP1916995B2 (en) | 2005-07-29 | 2022-06-29 | Stichting Groningen Centre for Drug Research | Ph-controlled pulsatile delivery system, methods for preparation and use thereof |
| US8912214B2 (en) | 2005-07-29 | 2014-12-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of Chk2 kinase inhibitors for cancer treatment |
| CN101300004B (zh) | 2005-09-23 | 2013-08-21 | 帕瑟洛吉卡有限公司 | 使用多胺类似物治疗病毒感染的方法 |
| WO2007040535A1 (en) | 2005-10-03 | 2007-04-12 | Cellgate, Inc. | Use of polyamine analogs for treatment and prevention of intestinal polyps |
| US20110091418A1 (en) | 2006-09-25 | 2011-04-21 | Pathlogica, LLC | Methods for treating viral infections using polyamine analogs |
| JP4929505B2 (ja) | 2006-10-31 | 2012-05-09 | Ｉｄｅｃ株式会社 | リレーソケット |
| WO2008112659A2 (en) * | 2007-03-09 | 2008-09-18 | Pathologica Llc | Regulation of osteopontin |
| CN101918206A (zh) | 2007-03-09 | 2010-12-15 | 赛科股份有限公司 | 再生棉板材及其制备方法 |
| WO2008112251A1 (en) | 2007-03-14 | 2008-09-18 | Progen Pharmaceuticals, Inc. | Cyclopropyl-containing polyamine analogs as disease therapies |
| WO2009018368A1 (en) | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders |
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| EP2355660A4 (en) | 2008-10-13 | 2012-05-02 | Biovista Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
| US9498431B2 (en) | 2008-12-10 | 2016-11-22 | Jianjian Xu | Controlled releasing composition |
| US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| NZ715686A (en) | 2009-07-16 | 2017-08-25 | Pathologica Llc | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| EP2283830A1 (en) | 2009-07-23 | 2011-02-16 | Actogenix N.V. | Aqueous enteric capsule coating |
| EP2343075A1 (en) | 2010-01-04 | 2011-07-13 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease |
| TWI520732B (zh) | 2011-01-18 | 2016-02-11 | 輝瑞有限公司 | 固體分子分散液 |
| PL2665471T3 (pl) | 2011-01-19 | 2018-06-29 | Pathologica, Llc. | Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg |
| WO2012112933A1 (en) * | 2011-02-18 | 2012-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| US10085955B2 (en) | 2013-01-08 | 2018-10-02 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
-
2014
- 2014-01-08 US US14/759,599 patent/US10085955B2/en active Active
- 2014-01-08 AU AU2014205529A patent/AU2014205529B2/en not_active Ceased
- 2014-01-08 BR BR112015016189A patent/BR112015016189A8/pt not_active Application Discontinuation
- 2014-01-08 EP EP21152182.8A patent/EP3831372A1/en not_active Withdrawn
- 2014-01-08 CN CN201480007129.3A patent/CN105163730B/zh not_active Expired - Fee Related
- 2014-01-08 ES ES14737914T patent/ES2859553T3/es active Active
- 2014-01-08 EP EP14737914.3A patent/EP2943189B1/en active Active
- 2014-01-08 JP JP2015551862A patent/JP6370804B2/ja not_active Expired - Fee Related
- 2014-01-08 CN CN201811424556.8A patent/CN109432073A/zh active Pending
- 2014-01-08 WO PCT/US2014/010714 patent/WO2014110154A1/en active Application Filing
- 2014-01-08 DK DK14737914.3T patent/DK2943189T3/da active
- 2014-01-08 CA CA2896977A patent/CA2896977C/en active Active
-
2015
- 2015-07-08 IL IL239851A patent/IL239851B/en active IP Right Grant
-
2016
- 2016-05-17 HK HK16105632.5A patent/HK1217451A1/zh unknown
-
2018
- 2018-07-10 JP JP2018130715A patent/JP2018172427A/ja active Pending
- 2018-08-23 US US16/109,824 patent/US10350178B2/en not_active Expired - Fee Related
- 2018-10-15 AU AU2018247351A patent/AU2018247351B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504389A5 (ja) | ||
| JP2016074740A5 (ja) | ||
| AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
| JP2016535777A5 (ja) | ||
| JP2018193377A5 (ja) | ||
| JP2018518537A5 (ja) | ||
| JP2015534562A5 (ja) | ||
| JP2007532663A5 (ja) | ||
| JP2009504748A5 (ja) | ||
| JP2006506378A5 (ja) | ||
| JP2014506583A5 (ja) | ||
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2018513188A5 (ja) | ||
| JP2019512528A5 (ja) | ||
| JP2019530713A5 (ja) | ||
| WO2014058979A3 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| JP2012517449A5 (ja) | ||
| EP4445951A3 (en) | Methods and compositions for treating sleep apnea | |
| JP2014520856A5 (ja) | ||
| JP2018530578A5 (ja) | ||
| JP2016510343A5 (ja) | ||
| JP2013544245A5 (ja) | ネプリライシンの発現および活性を増大させるための医薬組成物 | |
| JP2018512451A5 (ja) | ||
| JP2019515033A5 (ja) | ||
| Didona et al. | Resolution of a case of pediatric pemphigus vulgaris treated with rituximab |